Driehaus Builds Big Position in STSA Stock
According to a recent Form 13F filing submitted to the SEC, Driehaus Capital Management LLC disclosed a noteworthy and bullish investment in STSA stock. Here’s what you need to know about Satsuma Pharmaceuticals, Inc., as well as Driehaus Capital Management and their long position in shares of STSA stock:
About Driehaus Capital Management
Chicago, Illinois-based Driehaus Capital Management is an independent boutique investment adviser with roughly $12.5 billion in assets under management managing long-only equity and multi-asset alternative strategies.
About Satsuma Pharmaceuticals, Inc. (STSA)
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Driehaus Capital Management Buys Stock in STSA
According to the most recent 13F filed by Driehaus Capital Management, the firm added 1,714,046 shares of STSA stock to it holdings in the recent quarter. That brings their total long position in Satsuma Pharmaceuticals, Inc. to 1,714,046 shares, representing approximately 5.1743% of the 33,126,000 STSA shares outstanding. Based on the most recent closing price of $4.05 per share of STSA, the entire Driehaus Capital Management position in Satsuma Pharmaceuticals, Inc. is worth roughly $6,941,886.30.
Be sure to check out more recent 13F filings here to stay up to date on the latest disclosures from institutional investment managers like Driehaus Capital Management Llc. Also be sure to check out more recent 13F filing analysis news here.